GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Central Pharmaceuticals Ltd (DHA:CENTRALPHL) » Definitions » Net Income Including Noncontrolling Interests

Central Pharmaceuticals (DHA:CENTRALPHL) Net Income Including Noncontrolling Interests : BDT-68.10 Mil (TTM As of Sep. 2022)


View and export this data going back to 2013. Start your Free Trial

What is Central Pharmaceuticals Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Central Pharmaceuticals's Net Income Including Noncontrolling Interests for the three months ended in Sep. 2022 was BDT-9.08 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Sep. 2022 was BDT-68.10 Mil.


Central Pharmaceuticals Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Central Pharmaceuticals's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Central Pharmaceuticals Net Income Including Noncontrolling Interests Chart

Central Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only Premium Member Only 57.10 -1,107.00 -8.47 -68.25 -43.96

Central Pharmaceuticals Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Jun19 Sep19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Jun23
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.62 -9.27 -37.12 -9.08 -

Central Pharmaceuticals Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT-68.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Central Pharmaceuticals Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Central Pharmaceuticals's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.


Central Pharmaceuticals (DHA:CENTRALPHL) Business Description

Industry
Traded in Other Exchanges
N/A
Address
South West Darus Salam Road, 2-A/1, 2nd Floor, Mirpur - 1, Dhaka, BGD, 1216
Central Pharmaceuticals Ltd is engaged in the manufacturing and marketing of medicines in Bangladesh. The company manufactures finished formulation products for general people, hospitals, clinics, government organizations, corporations, and other non-government organizations. Its product portfolio encompasses therapeutic categories including gastrointestinal, anti-infective, vitamins and minerals, allergy cough and cold, analgesic and musculoskeletal, dermatological, oral rehydration salt, and others. The products are in the dosage forms of tablets, capsules, liquid, and ointments.

Central Pharmaceuticals (DHA:CENTRALPHL) Headlines

No Headlines